| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. S Yusuf, P Sleight, J Pogue, J Bosch, R Davies, G Dagenais The New England journal of medicine 342 (3), 145-153, 2000 | 8541 | 2000 |
| The effect of digoxin on mortality and morbidity in patients with heart failure Digitalis Investigation Group New England Journal of Medicine 336 (8), 525-533, 1997 | 3684 | 1997 |
| Hyperinsulinemia as an independent risk factor for ischemic heart disease JP Després, B Lamarche, P Mauriège, B Cantin, GR Dagenais, ... New England Journal of Medicine 334 (15), 952-958, 1996 | 2547 | 1996 |
| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2463 | 2017 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2431 | 2019 |
| Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries CK Chow, KK Teo, S Rangarajan, S Islam, R Gupta, A Avezum, ... Jama 310 (9), 959-968, 2013 | 2247 | 2013 |
| Vitamin E supplementation and cardiovascular events in high-risk patients. S Yusuf, G Dagenais, J Pogue, J Bosch, P Sleight The New England journal of medicine 342 (3), 154-160, 2000 | 2006 | 2000 |
| Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Qué bec Cardiovascular Study B Lamarche, A Tchernof, S Moorjani, B Cantin, GR Dagenais, PJ Lupien, ... Circulation 95 (1), 69-75, 1997 | 1582 | 1997 |
| Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort … S Yusuf, P Joseph, S Rangarajan, S Islam, A Mente, P Hystad, M Brauer, ... The Lancet 395 (10226), 795-808, 2020 | 1518 | 2020 |
| Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. E Lonn, J Bosch, S Yusuf, P Sheridan, J Pogue, JM Arnold, C Ross, ... Jama 293 (11), 1338-1347, 2005 | 1468 | 2005 |
| Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study M Dehghan, A Mente, X Zhang, S Swaminathan, W Li, V Mohan, R Iqbal, ... The Lancet 390 (10107), 2050-2062, 2017 | 1222 | 2017 |
| Cardiovascular risk and events in 17 low-, middle-, and high-income countries S Yusuf, S Rangarajan, K Teo, S Islam, W Li, L Liu, J Bo, Q Lou, F Lu, ... New England Journal of Medicine 371 (9), 818-827, 2014 | 1109 | 2014 |
| Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective … S Yusuf, S Islam, CK Chow, S Rangarajan, G Dagenais, R Diaz, R Gupta, ... The Lancet 378 (9798), 1231-1243, 2011 | 1099 | 2011 |
| Urinary sodium and potassium excretion, mortality, and cardiovascular events M O'Donnell, A Mente, S Rangarajan, MJ McQueen, X Wang, L Liu, H Yan, ... New England Journal of Medicine 371 (7), 612-623, 2014 | 1058 | 2014 |
| Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of … M St John Sutton, MA Pfeffer, T Plappert, JL Rouleau, LA Moye, ... Circulation 89 (1), 68-75, 1994 | 1047 | 1994 |
| Cholesterol lowering in intermediate-risk persons without cardiovascular disease S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ... New England Journal of Medicine 374 (21), 2021-2031, 2016 | 1034 | 2016 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 958 | 2018 |
| World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions S Kaptoge, L Pennells, D De Bacquer, MT Cooney, M Kavousi, G Stevens, ... The Lancet global health 7 (10), e1332-e1345, 2019 | 908 | 2019 |
| Association of cardiometabolic multimorbidity with mortality E Di Angelantonio, S Kaptoge, D Wormser, P Willeit, AS Butterworth, ... Jama 314 (1), 52-60, 2015 | 901 | 2015 |
| Blood-pressure lowering in intermediate-risk persons without cardiovascular disease EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ... New England Journal of Medicine 374 (21), 2009-2020, 2016 | 806 | 2016 |
